

On-site Poster Session Program

Day 2: December 18 (Saturday) 2021 at 13:40-14:20

Room 4

On-Site Poster Session Group 1

Chair: Dr. Hirayuki Enomoto (Japan)

13:40-13:45

#10027 Hepatoma-derived Growth Factor as a Potential Therapeutic Target for Hepatocellular Carcinoma

Dr. Hirayuki Enomoto (Japan)

13:45-13:50

#10034 Iron Chelator Deferasirox Alters Sorafenib-induced Programmed Cell Deaths of Hepatoma Cells

Dr. Wataru Jomen (Japan)

13:50-13:55

#10052 Combination Therapy with Lenvatinib and RFA for CP A Patients with HCC Exceeding up-to-7

Criteria

Dr. Kazushi Numata (Japan)

13:55-14:00

#10088 Examination of the Detectability of Spoke Wheel Pattern by Contrast Ultrasonography in FNH

Dr. Masahiro Ogawa (Japan)

14:00-14:05

#10011 Bezafibrate Treatment is Associated with Reduced Risk for Development of HCC in Patients with PBC

Dr. Atsushi Tanaka (Japan)

14:05-14:10

#10031 Safety of Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma

Dr. Hiroshi Numao (Japan)

On-site Poster Session Group 2

Chair: Dr. Fumitaka Suzuki (Japan)

13:40-13:45

#10010 Real Impact of Tumor Marker AFP and PIVKA-II in Detecting Very Small Hepatocellular Carcinoma

Dr. Akito Nozaki (Japan)

13:45-13:50

#10054 Circulating IGFBP-1 Provides Resistance to Molecular Targeted Agent in Hepatocellular Carcinoma

Dr. Hiroyuki Suzuki (Japan)

13:50-13:55

#10081 Relationship between Serum Kynurenine Level and Prognosis of Patients with Hepatocellular Carcinoma

Dr. Shigemune Bekki (Japan)

13:55-14:00

#10082 Measurement of Renal Vein and IVC in Patients with Cirrhotic Ascites and Congestive Liver

Dr. Masahiro Kaneko (Japan)

14:00-14:05

#10017 Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series

Dr. Naoki Matsumoto (Japan)

14:05-14:10

#10078 **An Autopsy Case of Ruptured Hepatocellular Carcinoma Following Administration of Lenvatinib**

Dr. Kumichika Uchida (Japan)

On-site Poster Session Group 3

Chair: Dr. Ryota Masuzaki (Japan)

13:40-13:45

#10083 **A Case of Mortality from an Incidental Intrahepatic Cholangiocarcinoma with Severe Cholecystitis**

Dr. Yoshie Kadota (Japan)

13:45-13:50

#10041 **Laparoscopic Surgery could be Most Frequently Employ as a Treatment for HCC in SVR era**

Dr. Shuntaro Obi (Japan)

13:50-13:55

#10044 **ATZ+BEV Therapy can Control Disease Activity in Patients Who Do Not Respond to Lenvatinib**

Dr. Shuntaro Obi (Japan)

13:55-14:00

#10038 **Incidence of HCC is Quite Different Depending on the History of HCC; A Prospective Study by 600 SVRs**

Dr. Shuntaro Obi (Japan)

14:00-14:05

#10039 **Beware of Carcinogenesis Other Than HCC; A Prospective Study by 600 SVRs**

Dr. Shuntaro Obi (Japan)

14:05-14:10

#10040 **Risk Factors for Occurrence of HCC after DAA Therapy; A Prospective Study by 600 SVRs**

Dr. Shuntaro Obi (Japan)

14:10-14:15

#10043 **Is Liver Carcinogenesis after SVR IM or MC? By Analysis of Gene Profiles**

Dr. Shuntaro Obi (Japan)

On-site Poster Session Group 4

Chair: Dr. Makiko Taniai (Japan)

13:40-13:45

#10021 **Major Signaling Pathway in Hepatocellular Carcinoma and Drug-matched Variants**

Dr. Kenji Amemiya (Japan)

13:45-13:50

#10065 **Phenotypic and Genetic Features of Multiple Nodules in HCC Based on Tumor Evolutionary Trait**

Dr. Yosuke Hirotsu (Japan)

13:50-13:55

#10019 **Impact of Hepatectomy for Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombus**

Dr. Shohei Komatsu (Japan)

13:55-14:00

#10084 **Conversion Surgery for Advanced Hepatocellular Carcinoma after Lenvatinib, a Case Report**

Dr. Kazuki Kato (Japan)

14:00-14:05

#10007 **TACE with Cisplatin Versus Epirubicin for Hepatocellular Carcinoma, a Randomised Controlled Trial**
Dr. Osamu Aramaki (Japan)

14:05-14:10

#10070 **Examination of the Effect of Embolization of Corona Enhancement Area on Local Tumor Recurrence**
Dr. Yukinobu Watanabe (Japan)

On-site Poster Session Group 5

Chair: Dr. Shinpei Sato (Japan)

13:40-13:45

#10085 **Experience of Antiviral Therapy in Patients Co-infected with HIV and Hepatitis Virus**
Dr. Yuki Haga (Japan)

13:45-13:50

#10036 **Levocarnitine Suppresses Lenvatinib-related Sarcopenia in Hepatocellular Carcinoma Patients**
Dr. Hironao Okubo (Japan)

13:50-13:55

#10025 **Clinical Features of Systemic Treatment in Japan**
Dr. Takaaki Tanaka (Japan)

13:55-14:00

#10022 **Clinical Trend of Japanese Patients with HCC in Progression of Aging Society: Clinical Role of RFA**
Dr. Shota Izumi (Japan)

14:00-14:05

#10037 **Two Cases of RFA for HCC in the Caudate Lobe; an Emerging Technique with Using Guided Needle Under CT**
Dr. Sae Yumita (Japan)

14:05-14:10

#10030 **The Cancer Risk in PSC and Ulcerative Colitis from 26 Years Retrospective Cohort Study in Japan**
Dr. Takashi Taida (Japan)

On-site Poster Session Group 6

Chair: Dr. Shintaro Yamazaki (Japan)

13:40-13:45

#10053 **Stereotactic Body Radiotherapy for Early-stage Hepatocellular Carcinoma: A Single-Center Experience**
Dr. Shunsuke Okuyama (Japan)

13:45-13:50

#10014 **Impact of Postoperative Complications on Survival of Hepatocellular Carcinoma Patients**
Dr. Hisashi Nakayama (Japan)

13:50-13:55

#10028 **Surgical Resection for Hepatocellular Carcinoma with Major Vascular Invasion**
Dr. Shintaro Yamazaki (Japan)

13:55-14:00

#10032 **Impact of Patient Age on Outcome after Resection for Hepatocellular carcinoma**
Dr. Masaharu Harada (Japan)

14:00-14:05

#10056 **Transient High Transaminase Elevation Does Not Affect on Short Term Outcomes after Liver Resection**
Dr. Yusuke Mitsuka (Japan)

14:05-14:10

#10003 **Sex-related Differences in Predictors of HCC Incidence after DAA Therapy in Patients with HCV**
Dr. Takao Watanabe (Japan)

E-Poster Session Program

E-Poster Presentation will be available through Website of APASL Oncology 2021

at <http://www.apasl-oncology2021.org/>

- #10001 **FBL is the Hub Gene of Pulmonary Metastasis in Hepatocellular Carcinoma**
Dr. Wen-Rui Wu (China)
- #10002 **Everolimus Protect IRI Through the Effect of Treg**
Dr. Li Zhu (China)
- #10013 **Durability of SVR in GT3 and GT6 Patients Treated with SOF/VEL with/without RBV from China**
Dr. Huagang Xiong (China)
- #10016 **Clinical Characteristics and Survival Analysis of Patients with HCC after HBV Negative**
Dr. Hong Li (China)
- #10018 **Characteristics of Genomic Profile of Hepatocellular Carcinoma after Sustained Virologic Response**
Dr. Hiroshi Ohyama (Japan)
- #10042 **A Case of Primary Biliary Cholangitis Undergoing RFA for Liver Metastasis of Cervical Cancer**
Dr. Ken Nogami (Japan)
- #10048 **Development of Novel Therapeutic Agents for HCC by Suppressing Soluble MICA through ADAM9 Inhibition**
Dr. Keita Ogawa (Japan)
- #10050 **Impacts of EZH2 Inhibitor UNC1999 on Tumor and Tumor Microenvironment in Hepatocellular Carcinoma**
Dr. Junjie Ao (Japan)
- #10051 **Efficacy of Sorafenib and Radiotherapy vs Sorafenib/Radiotherapy Monotherapy: A Systematic Review**
Dr. Rivaldo S. Heriyanto (Indonesia)
- #10055 **The Effect of Glucosylceramide Synthase Inhibitor on Liver Fibrosis Regression**
Dr. Terunao Iwanaga (Japan)
- #10057 **Stereotactic Body Radiation Therapy for Early-stage Hepatocellular Carcinoma**
Dr. Shigeki Yano (Japan)
- #10059 **Combination Therapy for Multiple HCC with Tyrosine Kinase Inhibitor and Radiofrequency Ablation**
Dr. Keita Maki (Japan)
- #10068 **Macrotrabecular Massive Feature in Tumor is Associated with a Higher Risk of the Recurrence of HCC**
Dr. Hyun Woong Lee (Korea)
- #10071 **Acidic Microenvironment Aggravates HIRI by Modulating M1-Polarization by PPAR-gama Signal**
Dr. Wei Ding (China)
- #10072 **Protection Mechanism of DDIT4 S-Nitrosylation in ROS**
Dr. Yunfei Duan (China)
- #10074 **Molecular Mechanism of CCL7 by BRG1 in Liver Injury**
Dr. Yunjie Lu (China)
- #10075 **Dynamic Gut Microbiome Affects the Efficacy of PD-1-based Immunotherapy in Hepatocellular Carcinoma**
Dr. Chan Xie (China)
- #10086 **Regorafenib for Taiwanese Patients with Unresectable HCC after Sorafenib Failure**
Dr. Ming-Lung Yu (Taiwan)
- #10087 **Education and information sharing method for the coming era in ablation**
Dr. Maki Tobarai (Japan)
- #10089 **MWA vs. RFA in Intermediate Stage Hepatocellular Carcinoma: A Retro-prospective Study**
Dr. Diana Alcantara Babaran (Philippines)